Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance

AbbVie IncTrade
YieldMax COIN Option Income Strategy ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $248.54 (market cap $441.94B), while YieldMax COIN Option Income Strategy ETF trades at $18.2. The key difference: AbbVie Inc pays a 2.77% dividend while YieldMax COIN Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

ABBVCONY
Market Cap
$441.94B
Sector
HealthIncome / Options Overlay
52-Week High
$263.58$76.50
52-Week Low
$197.38$17.80
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

YieldMax COIN Option Income Strategy ETF

CONY trades at $18.54, up 4.16% today, with a bearish technical signal from moving averages but oversold RSI levels. The ETF shows no fundamental valuation ratios available, and recent news highlights significant shareholder losses despite high distribution yields. Weekly dividends are consistently announced, but underlying performance concerns persist.

Outlook remains cautious due to bearish technicals and negative media sentiment emphasizing value erosion. Risks include reliance on options income strategy and Coinbase volatility. Analyst coverage suggests skepticism, with no bullish catalysts evident near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY